# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-16T13:26:27.813838
**Route:** OpenRouter + LaTeX
**Tokens:** 16829 in / 1827 out
**Response SHA256:** 953ff086c2b2f4c4

---

I checked the draft specifically for fatal errors in (1) data–design alignment, (2) regression sanity, (3) completeness, and (4) internal consistency. I did **not** find any violations that would make the empirical design impossible, the results mechanically broken, or the paper obviously incomplete.

### 1) DATA–DESIGN ALIGNMENT (CRITICAL)
- **Treatment timing vs. data coverage:** PDMP must-query adoption years in Appendix Table `\ref{tab:pdmp_dates}` run through **2022** (CA, WY). The main panel is **2011–2023**, so treatment timing is within coverage (max treatment year 2022 ≤ max data year 2023). No misalignment.
- **Post-treatment observations:** With data through 2023, cohorts treated in 2022 have at least **one post year (2023)**. Earlier cohorts have more. No “treated but no post-period” issue is apparent.
- **Treatment definition consistency:** The paper consistently defines exposure as the (population-weighted) share of contiguous neighbors with must-query mandates active, and uses the **≥50%** threshold for `HighExposure`. No table contradicts this definition.

### 2) REGRESSION SANITY (CRITICAL)
I scanned all reported regression tables for impossible/clearly broken outputs.

- **Table 1 (`\ref{tab:main}`):** Coefficients and SEs are within plausible ranges for deaths per 100,000; no extreme SEs, no impossible R²; Observations reported (637).
- **Table 2 (`\ref{tab:drugs}`):** Coefficients/SEs plausible; varying N is explained by suppression; R² within [0,1]; no NA/Inf/NaN.
- **Table 3 (`\ref{tab:heterogeneity}`):** Coefficients/SEs plausible; no pathological SE inflation; R² within [0,1].
- **Table 4 (`\ref{tab:thresholds}`):** Coefficients/SEs plausible; R² within [0,1].
- **Appendix placebo table (`\ref{tab:placebo}`):** Coefficients tiny and SEs reasonable; R² values within [0,1].

No fatal “collinearity artifact” signatures (e.g., astronomically large SEs, nonsensical coefficients), and no impossible summary stats in regression outputs.

### 3) COMPLETENESS (CRITICAL)
- No placeholders like **TBD/TODO/XXX/NA/NaN/Inf** appear in tables.
- Regression tables **report N (Observations)** and **standard errors**.
- The text references figures/tables that appear to exist in the LaTeX (e.g., `fig:trends`, `fig:eventstudy`, `tab:placebo`, `tab:pdmp_dates`). I can’t verify external PDF presence from the LaTeX alone, but there are no missing LaTeX labels/environments that would obviously break compilation or create a “referenced but not defined” element.

### 4) INTERNAL CONSISTENCY (CRITICAL)
- **Sample size consistency:** 49 states/DC × 13 years (2011–2023) = 637 state-years, matching Table `\ref{tab:summary}` and Table `\ref{tab:main}`.
- **Text-vs-table numeric consistency:** Key numbers in text align with the relevant tables (e.g., main TWFE coefficient 2.767 in Table `\ref{tab:main}`, placebo coefficients match Table `\ref{tab:placebo}` up to rounding).
- **Timing consistency:** Treatment start (first mandates 2012) and pre-period (2011) are consistent across the narrative and data description.

ADVISOR VERDICT: PASS